• FDA approves Onpattro, first treatment for polyneuropathy caused by rare genetic disease

    2 monthes ago - By Healio

    Scott Gottlieb
    The FDA approved patisiran infusion for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
    The approval of patisiran marks the first FDA-approved treatment for this disease, as well as the first approval of a new class of drugs called small interfering ribonucleic acid treatment.
    “This approval is part of a broader wave of advances that allow us to treat disease by actually targeting the root cause, enabling us to arrest or reverse a condition, rather than only being able to slow its
    Read more ...

     

  • FDA approves patisiran infusion for hereditary transthyretin-mediated amyloidosis

    2 monthes ago - By Healio

    The FDA announced that it has approved patisiran infusion for the treatment of patients with peripheral nerve disease caused by hereditary transthyretin-mediated amyloidosis.
    The treatment is the first of its kind to be approved by the FDA for patients with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis, and the first FDA approval for small interfering ribonucleic acid treatment, according to a press release from the agency.
    Hereditary transthyretin-mediated amyloidosis is a genetic disease that produces buildup of
    Read more ...

     

  • FDA OKs Patisiran for Polyneuropathy in hAATR

    2 monthes ago - By Medscape

    Patisiran is the first FDA-approved treatment for polyneuropathy caused by hATTR and the first RNA-based therapy to treat a rare disease.
    FDA Approvals
    Read more ...

     

  • Patisiran Wins Two Firsts With FDA Approval

    2 monthes ago - By MedPageToday

    RNAi drug OK'd to treat polyneuropathy from hereditary transthyretin amyloidosis
    Read more ...